E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Published on 11/29/2005 in the Prospect News Biotech Daily.

Adnavance Technologies gets $3.85 million in series A financing

By Jennifer Chiou

New York, Nov. 29 - Adnavance Technologies Inc. said it completed a $3.85 million series A round of financing.

Working Opportunity Fund led investors, which included BC Medical Innovations Fund, Canadian Medical Discoveries Fund and the Business Development Bank of Canada.

Adnavance also said it secured funding from The National Research Council's Industrial Research Assistance Program and The Natural Sciences and Engineering Research Council of Canada for its research and development programs.

"This financing provides the company with a stable foundation for continued growth, enabling us to accelerate our lead product development programs on the health care diagnostics side of our business, and progress our efforts to produce prototypes for industrial applications," chief executive officer Henry Geraedts said in a news release.

"We believe that this round of financing is an important endorsement of the development progress that Adnavance has made and a vote of confidence in the technology platform and product pipeline."

Proceeds from the financing will go toward the company's core M-DNA technology for DNA-based vaccines as well as the development of its conductivity technology for light-driven generation and storage of hydrogen.

Adnavance Technologies is a Vancouver, B.C., private nanobiotechnology company that develops biosensors and molecular detection devices.

Issuer:Adnavance Technologies Inc.
Issue:Preferred Stock
Amount:$3.85 million
Round:Series A
Investors:Working Opportunity Fund (lead), BC Medical Innovations Fund, Canadian Medical Discoveries Fund, Business Development Bank of Canada
Announcement date:Nov. 29

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.